サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1705600

ペプチド・オリゴヌクレオチドCDMOの世界市場レポート 2025年

Peptide And Oligonucleotide CDMO Global Market Report 2025

出版日
ページ情報
英文 200 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
ペプチド・オリゴヌクレオチドCDMOの世界市場レポート 2025年
出版日: 2025年04月01日
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ペプチド・オリゴヌクレオチドCDMO市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR11.9％で37億9,000万米ドルに成長します。予測期間の成長は、個別化医療に対する需要の高まり、バイオテクノロジーの進歩、アプリケーションの拡大、アウトソーシングの増加、慢性疾患の負担増などに起因しています。予測期間の主な動向としては、個別化治療、技術の進歩、品質管理の課題、世界展開、バイオ医薬品企業間の協力関係の強化などが挙げられます。

ペプチド・オリゴヌクレオチドCDMO市場は、個別化医療の導入拡大が成長の原動力となっています。個別化医療は、ヘルスケアの決定や治療を遺伝、ライフスタイル、環境などの個人の特性に合わせるものです。この動向は、ゲノム技術の進歩、分子レベルでの疾病メカニズムに対する深い洞察、患者の遺伝子プロファイルや病歴に合わせてカスタマイズされた、より的を絞った効果的な治療オプションに対する需要によって後押しされています。ペプチドやオリゴヌクレオチドの開発・製造受託機関（CDMO）は、個々の患者のニーズに合わせてカスタマイズされた治療用ペプチドやオリゴヌクレオチドを製造することで、個別化医療において極めて重要な役割を果たしています。例えば、2024年2月、FDAの医薬品評価研究センター（CDER）は、希少疾患患者のための16の新しい個別化治療を承認したが、これは前年から顕著に増加しました。その結果、個別化医療の採用が増加し、ペプチド・オリゴヌクレオチドCDMO市場を前進させています。

ペプチド・オリゴヌクレオチドCDMO市場の主要企業は、戦略的パートナーシップを結び、サービスの充実、技術力の強化、市場でのプレゼンス拡大を図っています。ペプチド開発・生産パートナーシップは、ペプチドベースの治療薬を開発・製造するための組織間の共同作業を伴う。例えば、2023年5月、PolyPeptide Group AGはNumaferm GmbHとペプチド開発・生産で提携しました。この提携は、ポリペプチドのcGMP製造能力と市場アクセスに加え、Numaferm社の持続可能なペプチド製造と生化学的生産プラットフォームに関する専門知識を活用するものです。その目的は、ペプチドベースの原薬をより持続可能な方法で製造するために、適切なペプチド候補の開発を共同で探求することです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界ペプチド・オリゴヌクレオチドCDMO PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
  • 最終用途産業の分析
  • 世界のペプチド・オリゴヌクレオチドCDMO市場：成長率分析
  • 世界のペプチド・オリゴヌクレオチドCDMO市場の実績：規模と成長, 2019-2024
  • 世界のペプチド・オリゴヌクレオチドCDMO市場の予測：規模と成長, 2024-2029, 2034F
  • 世界ペプチド・オリゴヌクレオチドCDMO総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界のペプチド・オリゴヌクレオチドCDMO市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • ペプチド
  • オリゴヌクレオチド
  • 世界のペプチド・オリゴヌクレオチドCDMO市場：サービスタイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 契約開発
  • 契約製造
  • 世界のペプチド・オリゴヌクレオチドCDMO市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 治療薬
  • 調査アプリケーション
  • 診断
  • その他の用途
  • 世界のペプチド・オリゴヌクレオチドCDMO市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • バイオ医薬品企業
  • 製薬会社
  • 調査機関
  • 学術機関および政府機関
  • その他エンドユーザー
  • 世界のペプチド・オリゴヌクレオチドCDMO市場ペプチドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 有効医薬品成分（アピス）
  • ペプチド医薬品
  • ペプチド合成・製造サービス
  • 世界のペプチド・オリゴヌクレオチドCDMO市場オリゴヌクレオチドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • アンチセンスオリゴヌクレオチド
  • sirnaおよびmrnaオリゴヌクレオチド
  • オリゴヌクレオチド合成・製造サービス

第7章 地域別・国別分析

  • 世界のペプチド・オリゴヌクレオチドCDMO市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 世界のペプチド・オリゴヌクレオチドCDMO市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • ペプチド・オリゴヌクレオチドCDMO市場：競合情勢
  • ペプチド・オリゴヌクレオチドCDMO市場：企業プロファイル
    • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
    • Ajinomoto Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Lonza Group Ag Overview, Products and Services, Strategy and Financial Analysis
    • Wuxi Apptec Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • Catalent Inc.
  • Piramal Pharma Ltd
  • Curia Global Inc.
  • Almac Group
  • Euroapi SA.
  • CordenPharma International
  • Bachem Holding AG
  • Genscript Biotech Corporation
  • PolyPeptide Group
  • Rentschler Biopharma SE
  • Ambiopharm Inc
  • ScinoPharm
  • Senn Chemicals AG
  • Aurigene Pharmaceutical Services
  • Creative Peptides

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • ペプチド・オリゴヌクレオチドCDMO市場2029：新たな機会を提供する国
  • ペプチド・オリゴヌクレオチドCDMO市場2029：新たな機会を提供するセグメント
  • ペプチド・オリゴヌクレオチドCDMO市場2029：成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r30918

A peptide and oligonucleotide CDMO (contract development and manufacturing organization) refers to a company that offers services for the development, manufacturing, and supply of peptides and oligonucleotide-based therapeutics. These organizations specialize in synthetic chemistry, process development, analytical testing, and cGMP manufacturing to support the production of peptides and oligonucleotides for various companies.

The main product types provided by peptide and oligonucleotide CDMOs are peptides and oligonucleotides. Peptides are short chains of amino acids, typically less than 50 amino acids in length, that play crucial roles in biological processes such as signaling and hormone regulation. These CDMOs offer services including contract development and contract manufacturing. Peptides and oligonucleotides find applications in therapeutics, research applications, diagnostics, and other fields, and are utilized by end-users such as biopharmaceutical companies, pharmaceutical companies, research institutes, academic and government organizations, among others.

The peptide and oligonucleotide CDMO market research report is one of a series of new reports from The Business Research Company that provides peptide and oligonucleotide CDMO market statistics, including the peptide and oligonucleotide CDMO industry global market size, regional shares, competitors with peptide and oligonucleotide CDMO market share, detailed peptide and oligonucleotide CDMO market segments, market trends, and opportunities, and any further data you may need to thrive in the peptide and oligonucleotide CDMO industry. These peptide and oligonucleotide CDMO market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The peptide and oligonucleotide cdmo market size has grown rapidly in recent years. It will grow from $2.16 billion in 2024 to $2.42 billion in 2025 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to a rise in demand for therapeutic agents, advancements in synthesis and manufacturing, personalized medicine trends, regulatory guidelines, and increased focus on antiviral peptides and mRNA vaccines highlighting the potential of oligonucleotides in vaccine development.

The peptide and oligonucleotide cdmo market size is expected to see rapid growth in the next few years. It will grow to $3.79 billion in 2029 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to the growing demand for personalized medicine, advancements in biotechnology, expanding applications, increasing outsourcing, and the growing burden of chronic diseases. Major trends in the forecast period include personalized therapies, technological advancements, quality control challenges, global expansion, and increased collaboration among biopharmaceutical companies.

The peptide and oligonucleotide CDMO markets are poised for growth, driven by the increasing adoption of personalized medicine. Personalized medicine tailors healthcare decisions and treatments to individual characteristics such as genetics, lifestyle, and environment. This trend is fueled by advancements in genomic technologies, deeper insights into disease mechanisms at the molecular level, and the demand for more targeted and effective treatment options customized to patients' genetic profiles and medical histories. Peptide and oligonucleotide contract development and manufacturing organizations (CDMOs) play a pivotal role in personalized medicine by producing customized therapeutic peptides and oligonucleotides to meet individual patient needs. For example, in February 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 16 new personalized treatments for rare disease patients, a notable increase from the previous year. Consequently, the rising adoption of personalized medicine is propelling the peptide and oligonucleotide CDMO market forward.

Key players in the peptide and oligonucleotide CDMO market are forging strategic partnerships to enrich their service offerings, enhance technological capabilities, and broaden market presence. Peptide development and production partnerships entail collaborative efforts between organizations to develop and manufacture peptide-based therapeutics. For instance, in May 2023, PolyPeptide Group AG teamed up with Numaferm GmbH for peptide development and production. This collaboration harnesses PolyPeptide's cGMP manufacturing capacities and market access alongside Numaferm's expertise in sustainable peptide manufacturing and biochemical production platforms. The aim is to jointly explore the development of suitable peptide candidates for more sustainable production of peptide-based APIs.

In May 2024, EUROAPI strengthened its foothold in the oligonucleotide CDMO market by acquiring BianoGMP, further enhancing its capacity in Frankfurt. BianoGMP, a Germany-based CDMO specializing in providing analytical services for oligonucleotides, augments EUROAPI's capabilities, positioning it for expanded growth and innovation in the oligonucleotide segment.

Major companies operating in the peptide and oligonucleotide cdmo market are Thermo Fisher Scientific Inc., Merck KGaA, Ajinomoto Co. Inc., Lonza Group Ag, Wuxi Apptec Co. Ltd., Catalent Inc., Piramal Pharma Ltd, Curia Global Inc., Almac Group, Euroapi SA., CordenPharma International, Bachem Holding AG, Genscript Biotech Corporation, PolyPeptide Group, Rentschler Biopharma SE, Ambiopharm Inc, ScinoPharm, Senn Chemicals AG, Aurigene Pharmaceutical Services, Creative Peptides, Sylentis S.A.

North America was the largest region in the peptide and oligonucleotide CDMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and oligonucleotide cdmo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the peptide and oligonucleotide cdmo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The peptide and oligonucleotide CDMO market consists of revenues earned by entities by providing services such as analytical testing, oligonucleotide synthesis services, and regulatory support. The market value includes the value of related goods sold by the service provider or included within the service offering. The peptide and oligonucleotide CDMO market also includes sales of custom peptides and custom oligonucleotides. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Peptide And Oligonucleotide CDMO Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on peptide and oligonucleotide cdmo market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for peptide and oligonucleotide cdmo ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The peptide and oligonucleotide cdmo market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Product: Peptides; Oligonucleotides
  • 2) By Service Type: Contract Development; Contract Manufacturing;
  • 3) By Application: Therapeutics; Research Applications; Diagnostics; Other Applications
  • 4) By End User: Biopharmaceutical Companies; Pharmaceutical Companies; Research Institutes; Academic and Government Organizations; Others End Users
  • Subsegments:
  • 1) By Peptides: Active Pharmaceutical Ingredients (Apis); Peptide Drug Products; Peptide Synthesis And Manufacturing Services
  • 2) By Oligonucleotides: Antisense Oligonucleotides; Sirna And Mrna Oligonucleotides; Oligonucleotide Synthesis And Manufacturing Services
  • Companies Mentioned: Thermo Fisher Scientific Inc.; Merck KGaA; Ajinomoto Co. Inc.; Lonza Group Ag; Wuxi Apptec Co. Ltd.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Peptide And Oligonucleotide CDMO Market Characteristics

3. Peptide And Oligonucleotide CDMO Market Trends And Strategies

4. Peptide And Oligonucleotide CDMO Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Peptide And Oligonucleotide CDMO Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Peptide And Oligonucleotide CDMO PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Peptide And Oligonucleotide CDMO Market Growth Rate Analysis
  • 5.4. Global Peptide And Oligonucleotide CDMO Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Peptide And Oligonucleotide CDMO Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Peptide And Oligonucleotide CDMO Total Addressable Market (TAM)

6. Peptide And Oligonucleotide CDMO Market Segmentation

  • 6.1. Global Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Peptides
  • Oligonucleotides
  • 6.2. Global Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Contract Development
  • Contract Manufacturing
  • 6.3. Global Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Therapeutics
  • Research Applications
  • Diagnostics
  • Other Applications
  • 6.4. Global Peptide And Oligonucleotide CDMO Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Biopharmaceutical Companies
  • Pharmaceutical Companies
  • Research Institutes
  • Academic and Government Organizations
  • Others End Users
  • 6.5. Global Peptide And Oligonucleotide CDMO Market, Sub-Segmentation Of Peptides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Active Pharmaceutical Ingredients (Apis)
  • Peptide Drug Products
  • Peptide Synthesis And Manufacturing Services
  • 6.6. Global Peptide And Oligonucleotide CDMO Market, Sub-Segmentation Of Oligonucleotides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Antisense Oligonucleotides
  • Sirna And Mrna Oligonucleotides
  • Oligonucleotide Synthesis And Manufacturing Services

7. Peptide And Oligonucleotide CDMO Market Regional And Country Analysis

  • 7.1. Global Peptide And Oligonucleotide CDMO Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Peptide And Oligonucleotide CDMO Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Peptide And Oligonucleotide CDMO Market

  • 8.1. Asia-Pacific Peptide And Oligonucleotide CDMO Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Peptide And Oligonucleotide CDMO Market

  • 9.1. China Peptide And Oligonucleotide CDMO Market Overview
  • 9.2. China Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Peptide And Oligonucleotide CDMO Market

  • 10.1. India Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Peptide And Oligonucleotide CDMO Market

  • 11.1. Japan Peptide And Oligonucleotide CDMO Market Overview
  • 11.2. Japan Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Peptide And Oligonucleotide CDMO Market

  • 12.1. Australia Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Peptide And Oligonucleotide CDMO Market

  • 13.1. Indonesia Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Peptide And Oligonucleotide CDMO Market

  • 14.1. South Korea Peptide And Oligonucleotide CDMO Market Overview
  • 14.2. South Korea Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Peptide And Oligonucleotide CDMO Market

  • 15.1. Western Europe Peptide And Oligonucleotide CDMO Market Overview
  • 15.2. Western Europe Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Peptide And Oligonucleotide CDMO Market

  • 16.1. UK Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Peptide And Oligonucleotide CDMO Market

  • 17.1. Germany Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Peptide And Oligonucleotide CDMO Market

  • 18.1. France Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Peptide And Oligonucleotide CDMO Market

  • 19.1. Italy Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Peptide And Oligonucleotide CDMO Market

  • 20.1. Spain Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Peptide And Oligonucleotide CDMO Market

  • 21.1. Eastern Europe Peptide And Oligonucleotide CDMO Market Overview
  • 21.2. Eastern Europe Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Peptide And Oligonucleotide CDMO Market

  • 22.1. Russia Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Peptide And Oligonucleotide CDMO Market

  • 23.1. North America Peptide And Oligonucleotide CDMO Market Overview
  • 23.2. North America Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Peptide And Oligonucleotide CDMO Market

  • 24.1. USA Peptide And Oligonucleotide CDMO Market Overview
  • 24.2. USA Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Peptide And Oligonucleotide CDMO Market

  • 25.1. Canada Peptide And Oligonucleotide CDMO Market Overview
  • 25.2. Canada Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Peptide And Oligonucleotide CDMO Market

  • 26.1. South America Peptide And Oligonucleotide CDMO Market Overview
  • 26.2. South America Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Peptide And Oligonucleotide CDMO Market

  • 27.1. Brazil Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Peptide And Oligonucleotide CDMO Market

  • 28.1. Middle East Peptide And Oligonucleotide CDMO Market Overview
  • 28.2. Middle East Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Peptide And Oligonucleotide CDMO Market

  • 29.1. Africa Peptide And Oligonucleotide CDMO Market Overview
  • 29.2. Africa Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Peptide And Oligonucleotide CDMO Market Competitive Landscape And Company Profiles

  • 30.1. Peptide And Oligonucleotide CDMO Market Competitive Landscape
  • 30.2. Peptide And Oligonucleotide CDMO Market Company Profiles
    • 30.2.1. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Ajinomoto Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Lonza Group Ag Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Wuxi Apptec Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Peptide And Oligonucleotide CDMO Market Other Major And Innovative Companies

  • 31.1. Catalent Inc.
  • 31.2. Piramal Pharma Ltd
  • 31.3. Curia Global Inc.
  • 31.4. Almac Group
  • 31.5. Euroapi SA.
  • 31.6. CordenPharma International
  • 31.7. Bachem Holding AG
  • 31.8. Genscript Biotech Corporation
  • 31.9. PolyPeptide Group
  • 31.10. Rentschler Biopharma SE
  • 31.11. Ambiopharm Inc
  • 31.12. ScinoPharm
  • 31.13. Senn Chemicals AG
  • 31.14. Aurigene Pharmaceutical Services
  • 31.15. Creative Peptides

32. Global Peptide And Oligonucleotide CDMO Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Peptide And Oligonucleotide CDMO Market

34. Recent Developments In The Peptide And Oligonucleotide CDMO Market

35. Peptide And Oligonucleotide CDMO Market High Potential Countries, Segments and Strategies

  • 35.1 Peptide And Oligonucleotide CDMO Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Peptide And Oligonucleotide CDMO Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Peptide And Oligonucleotide CDMO Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer